WO2021143701A1 - 嘧啶-4(3h)-酮类杂环化合物、其制备方法及其在医药学上的应用 - Google Patents
嘧啶-4(3h)-酮类杂环化合物、其制备方法及其在医药学上的应用 Download PDFInfo
- Publication number
- WO2021143701A1 WO2021143701A1 PCT/CN2021/071375 CN2021071375W WO2021143701A1 WO 2021143701 A1 WO2021143701 A1 WO 2021143701A1 CN 2021071375 W CN2021071375 W CN 2021071375W WO 2021143701 A1 WO2021143701 A1 WO 2021143701A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- ring
- cycloalkyl
- cyano
- group
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims abstract description 15
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 150000001875 compounds Chemical class 0.000 claims abstract description 97
- 150000003839 salts Chemical class 0.000 claims abstract description 46
- 238000000034 method Methods 0.000 claims abstract description 24
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 13
- 201000010099 disease Diseases 0.000 claims abstract description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 9
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 claims abstract description 7
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 6
- 201000011510 cancer Diseases 0.000 claims abstract description 5
- 101710116241 Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 claims abstract 5
- 125000000217 alkyl group Chemical group 0.000 claims description 99
- 239000000203 mixture Substances 0.000 claims description 63
- 125000001072 heteroaryl group Chemical group 0.000 claims description 44
- 229910052739 hydrogen Inorganic materials 0.000 claims description 44
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 43
- -1 antibody drugs Substances 0.000 claims description 38
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 36
- 229910052731 fluorine Inorganic materials 0.000 claims description 36
- 239000011737 fluorine Substances 0.000 claims description 36
- 125000000623 heterocyclic group Chemical group 0.000 claims description 31
- 125000001424 substituent group Chemical group 0.000 claims description 27
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 26
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 26
- 239000000651 prodrug Substances 0.000 claims description 25
- 229940002612 prodrug Drugs 0.000 claims description 25
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 24
- 229910052736 halogen Inorganic materials 0.000 claims description 24
- 150000002367 halogens Chemical class 0.000 claims description 24
- 229910052799 carbon Inorganic materials 0.000 claims description 21
- 125000004043 oxo group Chemical group O=* 0.000 claims description 21
- 229910052805 deuterium Inorganic materials 0.000 claims description 20
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 19
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 15
- 229910020008 S(O) Inorganic materials 0.000 claims description 13
- 125000004432 carbon atom Chemical group C* 0.000 claims description 12
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 12
- 229940079593 drug Drugs 0.000 claims description 11
- 230000000694 effects Effects 0.000 claims description 11
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 9
- 239000001257 hydrogen Substances 0.000 claims description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- 125000002837 carbocyclic group Chemical group 0.000 claims description 5
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims description 5
- 239000002246 antineoplastic agent Substances 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 206010029260 Neuroblastoma Diseases 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 206010029748 Noonan syndrome Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 241000282373 Panthera pardus Species 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 229940125644 antibody drug Drugs 0.000 claims description 2
- 239000000611 antibody drug conjugate Substances 0.000 claims description 2
- 229940049595 antibody-drug conjugate Drugs 0.000 claims description 2
- 229940041181 antineoplastic drug Drugs 0.000 claims description 2
- 229940044683 chemotherapy drug Drugs 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 239000003018 immunosuppressive agent Substances 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 239000003865 nucleic acid synthesis inhibitor Substances 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 230000002159 abnormal effect Effects 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- 229940125721 immunosuppressive agent Drugs 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 abstract description 7
- 230000001404 mediated effect Effects 0.000 abstract description 4
- 230000001105 regulatory effect Effects 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 237
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 207
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 147
- 239000000047 product Substances 0.000 description 125
- 230000002829 reductive effect Effects 0.000 description 113
- 238000004949 mass spectrometry Methods 0.000 description 106
- 239000000243 solution Substances 0.000 description 102
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 86
- 239000007787 solid Substances 0.000 description 82
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 76
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 66
- 238000010898 silica gel chromatography Methods 0.000 description 61
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 60
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 56
- 238000003756 stirring Methods 0.000 description 46
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 43
- 239000012074 organic phase Substances 0.000 description 43
- 239000011541 reaction mixture Substances 0.000 description 43
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 42
- 239000002904 solvent Substances 0.000 description 42
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 40
- 239000003208 petroleum Substances 0.000 description 40
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 38
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 34
- 229910052757 nitrogen Inorganic materials 0.000 description 33
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 30
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 27
- 238000005481 NMR spectroscopy Methods 0.000 description 24
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 20
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 20
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 20
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 18
- 239000000126 substance Substances 0.000 description 18
- 238000004007 reversed phase HPLC Methods 0.000 description 16
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 14
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 14
- 239000008346 aqueous phase Substances 0.000 description 13
- 238000000746 purification Methods 0.000 description 13
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 11
- 125000006413 ring segment Chemical group 0.000 description 11
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 10
- 238000001816 cooling Methods 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 10
- JMXKSZRRTHPKDL-UHFFFAOYSA-N titanium ethoxide Chemical compound [Ti+4].CC[O-].CC[O-].CC[O-].CC[O-] JMXKSZRRTHPKDL-UHFFFAOYSA-N 0.000 description 10
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 9
- CJQWLNNCQIHKHP-UHFFFAOYSA-N Ethyl 3-mercaptopropanoic acid Chemical compound CCOC(=O)CCS CJQWLNNCQIHKHP-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 239000012065 filter cake Substances 0.000 description 9
- 239000000706 filtrate Substances 0.000 description 9
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 239000012043 crude product Substances 0.000 description 8
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 8
- 239000012448 Lithium borohydride Substances 0.000 description 7
- 102100028516 Receptor-type tyrosine-protein phosphatase U Human genes 0.000 description 7
- XBXCNNQPRYLIDE-UHFFFAOYSA-M n-tert-butylcarbamate Chemical compound CC(C)(C)NC([O-])=O XBXCNNQPRYLIDE-UHFFFAOYSA-M 0.000 description 7
- 230000003287 optical effect Effects 0.000 description 7
- 229910000027 potassium carbonate Inorganic materials 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 6
- 230000002378 acidificating effect Effects 0.000 description 6
- 230000003197 catalytic effect Effects 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 239000002274 desiccant Substances 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 6
- OEAPCAURHYRHQQ-UHFFFAOYSA-N 2-chloro-5-iodo-1h-pyrimidin-6-one Chemical compound OC1=NC(Cl)=NC=C1I OEAPCAURHYRHQQ-UHFFFAOYSA-N 0.000 description 5
- UUAPHCNLERLEKD-UHFFFAOYSA-N 2-chloro-5-iodo-3-methylpyrimidin-4-one Chemical compound ClC1=NC=C(C(N1C)=O)I UUAPHCNLERLEKD-UHFFFAOYSA-N 0.000 description 5
- JTMMFCULRQVJGO-UNTBIKODSA-N CN(C1=O)C(N(CC2)CCC2(CCC2)[C@@H]2N)=NC=C1SC1=C(C=CN2)C2=NC=C1.Cl Chemical compound CN(C1=O)C(N(CC2)CCC2(CCC2)[C@@H]2N)=NC=C1SC1=C(C=CN2)C2=NC=C1.Cl JTMMFCULRQVJGO-UNTBIKODSA-N 0.000 description 5
- VXLDVQCNWTYFHN-GMUIIQOCSA-N CN(C1=O)C(N(CC2)CCC2(CCC2)[C@@H]2N)=NC=C1SC1=CC2=CC=NN2C=C1.Cl Chemical compound CN(C1=O)C(N(CC2)CCC2(CCC2)[C@@H]2N)=NC=C1SC1=CC2=CC=NN2C=C1.Cl VXLDVQCNWTYFHN-GMUIIQOCSA-N 0.000 description 5
- QFAXVLUYFXSWIQ-QGZVFWFLSA-N CN1N=C(C=CC(SC(C(N2C)=O)=CN=C2N(CC2)CCC2(COC2)[C@@H]2N)=C2Cl)C2=C1 Chemical compound CN1N=C(C=CC(SC(C(N2C)=O)=CN=C2N(CC2)CCC2(COC2)[C@@H]2N)=C2Cl)C2=C1 QFAXVLUYFXSWIQ-QGZVFWFLSA-N 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- 108091006146 Channels Proteins 0.000 description 5
- 150000007513 acids Chemical class 0.000 description 5
- 125000003118 aryl group Chemical group 0.000 description 5
- 125000004429 atom Chemical group 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 238000004809 thin layer chromatography Methods 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Substances IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 210000003722 extracellular fluid Anatomy 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 125000005842 heteroatom Chemical group 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000011535 reaction buffer Substances 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 4
- QORIMRSQLRAMSF-JGVFFNPUSA-N (3S,4S)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine Chemical compound C[C@@H]1OCC2(CCNCC2)[C@@H]1N QORIMRSQLRAMSF-JGVFFNPUSA-N 0.000 description 3
- HFRUPBVESRLIES-CSJMPQKXSA-N (R)-2-methyl-N-[(3S,4S)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-yl]propane-2-sulfinamide Chemical compound C[C@@H]1OCC2(CCNCC2)[C@@H]1N[S@](=O)C(C)(C)C HFRUPBVESRLIES-CSJMPQKXSA-N 0.000 description 3
- GLDRFUJFSNNWIM-UHFFFAOYSA-N 1,7-dihydropyrrolo[2,3-b]pyridine-4-thione Chemical compound S=C1C=CNC2=C1C=CN2 GLDRFUJFSNNWIM-UHFFFAOYSA-N 0.000 description 3
- ZISLUPNINLZWRT-UHFFFAOYSA-N 1h-indazole-5-thiol Chemical compound SC1=CC=C2NN=CC2=C1 ZISLUPNINLZWRT-UHFFFAOYSA-N 0.000 description 3
- DNCYBUMDUBHIJZ-UHFFFAOYSA-N 1h-pyrimidin-6-one Chemical compound O=C1C=CN=CN1 DNCYBUMDUBHIJZ-UHFFFAOYSA-N 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 3
- CVKNKNVZHOMOHD-UHFFFAOYSA-N 4-bromopyrazolo[1,5-a]pyridine Chemical compound BrC1=CC=CN2N=CC=C12 CVKNKNVZHOMOHD-UHFFFAOYSA-N 0.000 description 3
- GMGRNRQBEWCLKJ-UHFFFAOYSA-N 5-bromo-4-chloro-1h-indazole Chemical compound ClC1=C(Br)C=CC2=C1C=NN2 GMGRNRQBEWCLKJ-UHFFFAOYSA-N 0.000 description 3
- SJEWBDKBNBCUSQ-UHFFFAOYSA-N 5-bromo-4-chloro-2-methylindazole Chemical compound BrC1=C(C2=CN(N=C2C=C1)C)Cl SJEWBDKBNBCUSQ-UHFFFAOYSA-N 0.000 description 3
- KGNOVCZNYCRKPG-UHFFFAOYSA-N 5-bromo-4-chloro-2-methylindazole-3-carbaldehyde Chemical compound BrC1=C(C2=C(N(N=C2C=C1)C)C=O)Cl KGNOVCZNYCRKPG-UHFFFAOYSA-N 0.000 description 3
- WIXLWTSIJGQDLJ-UHFFFAOYSA-N 5-bromo-4-chloropyrazolo[1,5-a]pyridine Chemical compound Clc1c(Br)ccn2nccc12 WIXLWTSIJGQDLJ-UHFFFAOYSA-N 0.000 description 3
- DZANYXOTJVLAEE-UHFFFAOYSA-N 6,8-difluoro-4-methylumbelliferyl phosphate Chemical compound FC1=C(OP(O)(O)=O)C(F)=CC2=C1OC(=O)C=C2C DZANYXOTJVLAEE-UHFFFAOYSA-N 0.000 description 3
- MCWBXSSDBPTWRX-UHFFFAOYSA-N 6-amino-5-bromo-3-methyl-1h-pyrimidine-2,4-dione Chemical compound CN1C(=O)NC(N)=C(Br)C1=O MCWBXSSDBPTWRX-UHFFFAOYSA-N 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- WZWZTMIMOQCAIQ-UHFFFAOYSA-N C(=O)=C1COCC11CCN(CC1)C(=O)OC(C)(C)C Chemical compound C(=O)=C1COCC11CCN(CC1)C(=O)OC(C)(C)C WZWZTMIMOQCAIQ-UHFFFAOYSA-N 0.000 description 3
- WLYSPMKYLCTUCX-NSHDSACASA-N C(C)(C)(C)OC(=O)N1CCC2(C([C@@H](OC2)C)=C=O)CC1 Chemical compound C(C)(C)(C)OC(=O)N1CCC2(C([C@@H](OC2)C)=C=O)CC1 WLYSPMKYLCTUCX-NSHDSACASA-N 0.000 description 3
- ANGBALMMNYAKSP-UHFFFAOYSA-N C1(=C(C=2C(C=C1)=NN(C=2C#N)C)Cl)Br Chemical compound C1(=C(C=2C(C=C1)=NN(C=2C#N)C)Cl)Br ANGBALMMNYAKSP-UHFFFAOYSA-N 0.000 description 3
- PUOGYUVYLGIUNK-UHFFFAOYSA-N C1(=CC=NC2=C1C=CN2C)SCCC(=O)OCC Chemical compound C1(=CC=NC2=C1C=CN2C)SCCC(=O)OCC PUOGYUVYLGIUNK-UHFFFAOYSA-N 0.000 description 3
- DHFFUYMZSCMBMI-UHFFFAOYSA-N C1=2NN=CC1=C(SCCC(=O)OCC)C=CC=2 Chemical compound C1=2NN=CC1=C(SCCC(=O)OCC)C=CC=2 DHFFUYMZSCMBMI-UHFFFAOYSA-N 0.000 description 3
- VIBQWBONENRIAL-UHFFFAOYSA-N C1=CC=C(C=2N1N=CC=2)SCCC(=O)OCC Chemical compound C1=CC=C(C=2N1N=CC=2)SCCC(=O)OCC VIBQWBONENRIAL-UHFFFAOYSA-N 0.000 description 3
- IDALKARRADLQOD-UHFFFAOYSA-N CCOC(C1=C(C(Cl)=C(C=C2)Br)N2N=C1)=O Chemical compound CCOC(C1=C(C(Cl)=C(C=C2)Br)N2N=C1)=O IDALKARRADLQOD-UHFFFAOYSA-N 0.000 description 3
- HXCQHESRXHMCHB-UHFFFAOYSA-N CCOC(CCSC(C=CC1=NN(C)C(C#N)=C11)=C1Cl)=O Chemical compound CCOC(CCSC(C=CC1=NN(C)C(C#N)=C11)=C1Cl)=O HXCQHESRXHMCHB-UHFFFAOYSA-N 0.000 description 3
- WIGHROAGELPFFR-UHFFFAOYSA-N CCOC(CCSC1=CC2=CC=NN2C=C1)=O Chemical compound CCOC(CCSC1=CC2=CC=NN2C=C1)=O WIGHROAGELPFFR-UHFFFAOYSA-N 0.000 description 3
- QNSCUCXAPHCKBC-UHFFFAOYSA-N CCOC(CCSC1=CC=C2NN=CC2=C1)=O Chemical compound CCOC(CCSC1=CC=C2NN=CC2=C1)=O QNSCUCXAPHCKBC-UHFFFAOYSA-N 0.000 description 3
- VHFAFENJONRRGO-UHFFFAOYSA-N CN(C1=C=O)C(N(CC2)CCC2(CCC2)C2=O)=NC(N)=C1Br Chemical compound CN(C1=C=O)C(N(CC2)CCC2(CCC2)C2=O)=NC(N)=C1Br VHFAFENJONRRGO-UHFFFAOYSA-N 0.000 description 3
- PZDVVYGCWLMSQU-UHFFFAOYSA-N CN(C1=C=O)C(N(CC2)CCC2(CCC2)C2=O)=NC=C1I Chemical compound CN(C1=C=O)C(N(CC2)CCC2(CCC2)C2=O)=NC=C1I PZDVVYGCWLMSQU-UHFFFAOYSA-N 0.000 description 3
- KASLSASWTSIFPW-UHFFFAOYSA-N CN1N=C(C=CC(Br)=C2Cl)C2=C1C=NO Chemical compound CN1N=C(C=CC(Br)=C2Cl)C2=C1C=NO KASLSASWTSIFPW-UHFFFAOYSA-N 0.000 description 3
- RRIGRZONSCCFNJ-UHFFFAOYSA-M CN1N=C(C=CC([S-])=C2Cl)C2=C1.[Na+] Chemical compound CN1N=C(C=CC([S-])=C2Cl)C2=C1.[Na+] RRIGRZONSCCFNJ-UHFFFAOYSA-M 0.000 description 3
- LZQXTIDIIWAMSD-MATQGCILSA-N C[C@@H]1OCC(CC2)(CCN2C(N(C)C2=C=O)=NC(N)=C2I)[C@@H]1N[S@@](C(C)(C)C)=O Chemical compound C[C@@H]1OCC(CC2)(CCN2C(N(C)C2=C=O)=NC(N)=C2I)[C@@H]1N[S@@](C(C)(C)C)=O LZQXTIDIIWAMSD-MATQGCILSA-N 0.000 description 3
- DYBOZWXXXSWVPR-SIFKYCAASA-N C[C@@H]1OCC(CC2)(CCN2C(N(C)C2=C=O)=NC(N)=C2SC(C=CC2=NN(C)C=C22)=C2Cl)[C@@H]1N[S@@](C(C)(C)C)=O Chemical compound C[C@@H]1OCC(CC2)(CCN2C(N(C)C2=C=O)=NC(N)=C2SC(C=CC2=NN(C)C=C22)=C2Cl)[C@@H]1N[S@@](C(C)(C)C)=O DYBOZWXXXSWVPR-SIFKYCAASA-N 0.000 description 3
- YZMOVRPHYIBHJN-JTQLQIEISA-N C[C@@H]1OCC(CC2)(CCN2C(N(C)C2=C=O)=NC=C2I)C1=O Chemical compound C[C@@H]1OCC(CC2)(CCN2C(N(C)C2=C=O)=NC=C2I)C1=O YZMOVRPHYIBHJN-JTQLQIEISA-N 0.000 description 3
- MDOJXIKVCPUMLL-JTQLQIEISA-N C[C@@H]1OCC(CC2)(CCN2C(N2C)=NC(N)=CC2=C=O)C1=O Chemical compound C[C@@H]1OCC(CC2)(CCN2C(N2C)=NC(N)=CC2=C=O)C1=O MDOJXIKVCPUMLL-JTQLQIEISA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- 101001087416 Homo sapiens Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- ZLFUVCOPKKGIMX-UHFFFAOYSA-N N1=C2C(=CN1C)C(Cl)=C(SCCC(=O)OCC)C=C2 Chemical compound N1=C2C(=CN1C)C(Cl)=C(SCCC(=O)OCC)C=C2 ZLFUVCOPKKGIMX-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- 102000004257 Potassium Channel Human genes 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- GQYKAVVHOOFOKR-UHFFFAOYSA-N SC1=CC2=CC=NN2C=C1 Chemical compound SC1=CC2=CC=NN2C=C1 GQYKAVVHOOFOKR-UHFFFAOYSA-N 0.000 description 3
- NZZZSXRVUVMSGY-FEHNQZOVSA-N [2H]C([2H])([2H])N(C1=O)C(N(CC2)CCC2(CO[C@H]2C)[C@@H]2N)=NC=C1I Chemical compound [2H]C([2H])([2H])N(C1=O)C(N(CC2)CCC2(CO[C@H]2C)[C@@H]2N)=NC=C1I NZZZSXRVUVMSGY-FEHNQZOVSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- CHKQALUEEULCPZ-UHFFFAOYSA-N amino 2,4,6-trimethylbenzenesulfonate Chemical compound CC1=CC(C)=C(S(=O)(=O)ON)C(C)=C1 CHKQALUEEULCPZ-UHFFFAOYSA-N 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 150000001733 carboxylic acid esters Chemical class 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- CSNZZVJLCGOAFL-UHFFFAOYSA-N ethyl 4-bromopyrazolo[1,5-a]pyridine-3-carboxylate Chemical compound C1=CC=C(Br)C2=C(C(=O)OCC)C=NN21 CSNZZVJLCGOAFL-UHFFFAOYSA-N 0.000 description 3
- 239000012046 mixed solvent Substances 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 125000003367 polycyclic group Chemical group 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 108020001213 potassium channel Proteins 0.000 description 3
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 150000003456 sulfonamides Chemical class 0.000 description 3
- ZJHPQXGWLAIUFF-UHFFFAOYSA-N tert-butyl 4-(1,2-dihydroxyethyl)-4-(hydroxymethyl)piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(CO)(C(O)CO)CC1 ZJHPQXGWLAIUFF-UHFFFAOYSA-N 0.000 description 3
- CBOCJJSLVIKZOD-VUWPPUDQSA-N tert-butyl 4-[(2S)-1,2-dihydroxypropyl]-4-(hydroxymethyl)piperidine-1-carboxylate Chemical compound C[C@H](O)C(O)C1(CO)CCN(CC1)C(=O)OC(C)(C)C CBOCJJSLVIKZOD-VUWPPUDQSA-N 0.000 description 3
- 125000003396 thiol group Chemical group [H]S* 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- CESUXLKAADQNTB-SSDOTTSWSA-N 2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@](N)=O CESUXLKAADQNTB-SSDOTTSWSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- JEDALECUOKHQDK-UHFFFAOYSA-M 4-ethyl-1-[(2-methylpropan-2-yl)oxycarbonyl]piperidine-4-carboxylate Chemical compound CCC1(C([O-])=O)CCN(C(=O)OC(C)(C)C)CC1 JEDALECUOKHQDK-UHFFFAOYSA-M 0.000 description 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- 125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 description 2
- JGAVPFNFAUWIJY-UHFFFAOYSA-N 6-amino-3-methyl-1h-pyrimidine-2,4-dione Chemical compound CN1C(=O)C=C(N)NC1=O JGAVPFNFAUWIJY-UHFFFAOYSA-N 0.000 description 2
- LSFCLYRZJPQJHA-UHFFFAOYSA-N 8-azaspiro[4.5]decan-4-one Chemical compound O=C1CCCC11CCNCC1 LSFCLYRZJPQJHA-UHFFFAOYSA-N 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 description 2
- 101710144268 B- and T-lymphocyte attenuator Proteins 0.000 description 2
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 238000006646 Dess-Martin oxidation reaction Methods 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
- 241000790917 Dioxys <bee> Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 2
- 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- KYIXAOJPBHKKMO-UHFFFAOYSA-M [S-]C(C=CN1N=CC=C11)=C1Cl.[Na+] Chemical compound [S-]C(C=CN1N=CC=C11)=C1Cl.[Na+] KYIXAOJPBHKKMO-UHFFFAOYSA-M 0.000 description 2
- GOKWXBOMYFZFEK-UHFFFAOYSA-M [S-]C1=CC=CN2N=CC=C12.[Na+] Chemical compound [S-]C1=CC=CN2N=CC=C12.[Na+] GOKWXBOMYFZFEK-UHFFFAOYSA-M 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 239000012300 argon atmosphere Substances 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 238000005815 base catalysis Methods 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 238000006482 condensation reaction Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000030609 dephosphorylation Effects 0.000 description 2
- 238000006209 dephosphorylation reaction Methods 0.000 description 2
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- FMVJYQGSRWVMQV-UHFFFAOYSA-N ethyl propiolate Chemical compound CCOC(=O)C#C FMVJYQGSRWVMQV-UHFFFAOYSA-N 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 150000002391 heterocyclic compounds Chemical class 0.000 description 2
- TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Chemical compound OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- WLJVNTCWHIRURA-UHFFFAOYSA-N pimelic acid Chemical compound OC(=O)CCCCCC(O)=O WLJVNTCWHIRURA-UHFFFAOYSA-N 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 238000003419 tautomerization reaction Methods 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 1
- HLMWRMCHYCNINO-ZETCQYMHSA-N (3S)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-one Chemical compound C[C@H]1C(=O)C2(CCNCC2)CO1 HLMWRMCHYCNINO-ZETCQYMHSA-N 0.000 description 1
- GEQJYJIUAFUJBJ-WIFINTHYSA-N (3S,4S)-4-[[(R)-tert-butylsulfinyl]amino]-3-methyl-2-oxa-8-azaspiro[4.5]decane-8-carboxylic acid Chemical compound C[C@@H]1OCC2(CCN(CC2)C(O)=O)[C@@H]1N[S@](=O)C(C)(C)C GEQJYJIUAFUJBJ-WIFINTHYSA-N 0.000 description 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 description 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- UZHVXJZEHGSWQV-UHFFFAOYSA-N 1,2,3,3a,4,5,6,6a-octahydrocyclopenta[c]pyrrole Chemical compound C1NCC2CCCC21 UZHVXJZEHGSWQV-UHFFFAOYSA-N 0.000 description 1
- FTTATHOUSOIFOQ-UHFFFAOYSA-N 1,2,3,4,6,7,8,8a-octahydropyrrolo[1,2-a]pyrazine Chemical compound C1NCCN2CCCC21 FTTATHOUSOIFOQ-UHFFFAOYSA-N 0.000 description 1
- 125000005918 1,2-dimethylbutyl group Chemical group 0.000 description 1
- PBYZOLVKZWGSBB-UHFFFAOYSA-N 1-benzyl-4-methylpiperidine-4-carbonitrile Chemical compound C1CC(C)(C#N)CCN1CC1=CC=CC=C1 PBYZOLVKZWGSBB-UHFFFAOYSA-N 0.000 description 1
- LCEKUTIKCBBCEX-UHFFFAOYSA-N 1-methyl-7H-pyrrolo[2,3-b]pyridine-4-thione Chemical compound CN1C=CC2=C(C=CN=C12)S LCEKUTIKCBBCEX-UHFFFAOYSA-N 0.000 description 1
- PVJZBZSCGJAWNG-UHFFFAOYSA-N 2,4,6-trimethylbenzenesulfonyl chloride Chemical compound CC1=CC(C)=C(S(Cl)(=O)=O)C(C)=C1 PVJZBZSCGJAWNG-UHFFFAOYSA-N 0.000 description 1
- RGJNPJRAXMSHKN-UHFFFAOYSA-N 2,4-dichloro-5-iodopyrimidine Chemical compound ClC1=NC=C(I)C(Cl)=N1 RGJNPJRAXMSHKN-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- RECARUFTCUAFPV-UHFFFAOYSA-N 2-oxa-7-azaspiro[3.5]nonane Chemical compound C1OCC11CCNCC1 RECARUFTCUAFPV-UHFFFAOYSA-N 0.000 description 1
- KOZYKOWWRIYUAJ-UHFFFAOYSA-N 2-oxa-8-azaspiro[4.5]decan-4-one Chemical compound O=C1COCC11CCNCC1 KOZYKOWWRIYUAJ-UHFFFAOYSA-N 0.000 description 1
- LKDJYZBKCVSODK-UHFFFAOYSA-N 3,8-diazabicyclo[3.2.1]octane Chemical compound C1NCC2CCC1N2 LKDJYZBKCVSODK-UHFFFAOYSA-N 0.000 description 1
- NYPYPOZNGOXYSU-UHFFFAOYSA-N 3-bromopyridine Chemical compound BrC1=CC=CN=C1 NYPYPOZNGOXYSU-UHFFFAOYSA-N 0.000 description 1
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- WZHKLWVRBGNOFE-UHFFFAOYSA-N 4-bromo-1-methylpyrrolo[2,3-b]pyridine Chemical compound C1=CN=C2N(C)C=CC2=C1Br WZHKLWVRBGNOFE-UHFFFAOYSA-N 0.000 description 1
- KJIODOACRIRBPB-UHFFFAOYSA-N 4-bromo-1h-indazole Chemical compound BrC1=CC=CC2=C1C=NN2 KJIODOACRIRBPB-UHFFFAOYSA-N 0.000 description 1
- LEZHTYOQWQEBLH-UHFFFAOYSA-N 4-bromo-1h-pyrrolo[2,3-b]pyridine Chemical compound BrC1=CC=NC2=C1C=CN2 LEZHTYOQWQEBLH-UHFFFAOYSA-N 0.000 description 1
- IAWSZYHMEPZGKK-UHFFFAOYSA-N 4-bromo-3-chloro-2-methylaniline Chemical compound CC1=C(N)C=CC(Br)=C1Cl IAWSZYHMEPZGKK-UHFFFAOYSA-N 0.000 description 1
- CXXVUKYIBWZKHL-UHFFFAOYSA-N 4-bromo-3-chloropyridine Chemical compound ClC1=CN=CC=C1Br CXXVUKYIBWZKHL-UHFFFAOYSA-N 0.000 description 1
- HOXWESKAHYABGO-UHFFFAOYSA-N 5-azaspiro[2.4]heptane Chemical compound C1CC11CNCC1 HOXWESKAHYABGO-UHFFFAOYSA-N 0.000 description 1
- STVHMYNPQCLUNJ-UHFFFAOYSA-N 5-bromo-1h-indazole Chemical compound BrC1=CC=C2NN=CC2=C1 STVHMYNPQCLUNJ-UHFFFAOYSA-N 0.000 description 1
- WQOAKXFBWOXJNG-UHFFFAOYSA-N 5-bromopyrazolo[1,5-a]pyridine Chemical compound C1=C(Br)C=CN2N=CC=C21 WQOAKXFBWOXJNG-UHFFFAOYSA-N 0.000 description 1
- YGUFCDOEKKVKJK-UHFFFAOYSA-N 6-(4-amino-4-methylpiperidin-1-yl)-3-(2,3-dichlorophenyl)pyrazin-2-amine Chemical compound NC1(CCN(CC1)C1=CN=C(C(=N1)N)C1=C(C(=CC=C1)Cl)Cl)C YGUFCDOEKKVKJK-UHFFFAOYSA-N 0.000 description 1
- SFHYNDMGZXWXBU-LIMNOBDPSA-N 6-amino-2-[[(e)-(3-formylphenyl)methylideneamino]carbamoylamino]-1,3-dioxobenzo[de]isoquinoline-5,8-disulfonic acid Chemical compound O=C1C(C2=3)=CC(S(O)(=O)=O)=CC=3C(N)=C(S(O)(=O)=O)C=C2C(=O)N1NC(=O)N\N=C\C1=CC=CC(C=O)=C1 SFHYNDMGZXWXBU-LIMNOBDPSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 230000007730 Akt signaling Effects 0.000 description 1
- 101100096578 Arabidopsis thaliana SQD2 gene Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- CHAUHJGVQLFHMS-UHFFFAOYSA-N C.[I] Chemical class C.[I] CHAUHJGVQLFHMS-UHFFFAOYSA-N 0.000 description 1
- 0 CC(C)(C(*)(*)C1)C(*)(*)CN1C(N(*)C1=O)=NC(**)=C1SC1=CC2=CC=CC=CC2=CC=C1 Chemical compound CC(C)(C(*)(*)C1)C(*)(*)CN1C(N(*)C1=O)=NC(**)=C1SC1=CC2=CC=CC=CC2=CC=C1 0.000 description 1
- CESUXLKAADQNTB-ZETCQYMHSA-N CC(C)(C)[S@@](N)=O Chemical compound CC(C)(C)[S@@](N)=O CESUXLKAADQNTB-ZETCQYMHSA-N 0.000 description 1
- NXARZTDHEFUBLN-BUFIKQNTSA-N CC(C)(C)[S@](N[C@H](CCC1)C1(CC1)CCN1C(N(C)C1=C=O)=NC=C1SC1=C(C=CN2)C2=NC=C1)=O Chemical compound CC(C)(C)[S@](N[C@H](CCC1)C1(CC1)CCN1C(N(C)C1=C=O)=NC=C1SC1=C(C=CN2)C2=NC=C1)=O NXARZTDHEFUBLN-BUFIKQNTSA-N 0.000 description 1
- JEMDCVCKWNYLRR-UHFFFAOYSA-N CCOC(CCSC(C=CN1N=CC=C11)=C1Cl)=O Chemical compound CCOC(CCSC(C=CN1N=CC=C11)=C1Cl)=O JEMDCVCKWNYLRR-UHFFFAOYSA-N 0.000 description 1
- DBDHSWDMIZZXJX-JTQLQIEISA-N C[C@@H](C1)OCC1(CC1)CCN1C(N(C)C1=O)=NC=C1I Chemical compound C[C@@H](C1)OCC1(CC1)CCN1C(N(C)C1=O)=NC=C1I DBDHSWDMIZZXJX-JTQLQIEISA-N 0.000 description 1
- UMNWANSVHBASSJ-WIFDGKOVSA-N C[C@@H]1OCC(CC2)(CCN2C(N(C)C2=C=O)=NC=C2SC(C=CC2=NN(C)C=C22)=C2Cl)[C@@H]1N[S@@](C(C)(C)C)=O Chemical compound C[C@@H]1OCC(CC2)(CCN2C(N(C)C2=C=O)=NC=C2SC(C=CC2=NN(C)C=C22)=C2Cl)[C@@H]1N[S@@](C(C)(C)C)=O UMNWANSVHBASSJ-WIFDGKOVSA-N 0.000 description 1
- INXJSNKAKAASDY-SCLBCKFNSA-N C[C@@H]1OCC(CC2)(CCN2C(N(C)C2=O)=NC=C2Sc(cc[n]2nccc22)c2Cl)[C@@H]1N Chemical compound C[C@@H]1OCC(CC2)(CCN2C(N(C)C2=O)=NC=C2Sc(cc[n]2nccc22)c2Cl)[C@@H]1N INXJSNKAKAASDY-SCLBCKFNSA-N 0.000 description 1
- WHLHSDQDXKEVJZ-VXCUUSCGSA-N C[C@@H]1OCC(CC2)(CCN2C(N(C)C2=O)=NC=C2Sc(cc[n]2nccc22)c2Cl)[C@@H]1N[S@](C(C)(C)C)=O Chemical compound C[C@@H]1OCC(CC2)(CCN2C(N(C)C2=O)=NC=C2Sc(cc[n]2nccc22)c2Cl)[C@@H]1N[S@](C(C)(C)C)=O WHLHSDQDXKEVJZ-VXCUUSCGSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical group [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000801643 Homo sapiens Retinal-specific phospholipid-transporting ATPase ABCA4 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 1
- 102100025087 Insulin receptor substrate 1 Human genes 0.000 description 1
- 101710201824 Insulin receptor substrate 1 Proteins 0.000 description 1
- 230000004163 JAK-STAT signaling pathway Effects 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- FUAKLHDTUSWVIJ-UHFFFAOYSA-N N1C2=C(C=C1)C(SCCC(=O)OCC)=CC=N2 Chemical compound N1C2=C(C=C1)C(SCCC(=O)OCC)=CC=N2 FUAKLHDTUSWVIJ-UHFFFAOYSA-N 0.000 description 1
- NIRKXEAHIGDACK-UHFFFAOYSA-M N1C=CC2=C1N=CC=C2[S-].[Na+] Chemical compound N1C=CC2=C1N=CC=C2[S-].[Na+] NIRKXEAHIGDACK-UHFFFAOYSA-M 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 108010032107 Non-Receptor Type 11 Protein Tyrosine Phosphatase Proteins 0.000 description 1
- 102000007607 Non-Receptor Type 11 Protein Tyrosine Phosphatase Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 108010026552 Proteome Proteins 0.000 description 1
- 102100033617 Retinal-specific phospholipid-transporting ATPase ABCA4 Human genes 0.000 description 1
- 108050003452 SH2 domains Proteins 0.000 description 1
- 102000014400 SH2 domains Human genes 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- IKUYEYLZXGGCRD-ORAYPTAESA-N [3-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6-(2,3-dichlorophenyl)-5-methylpyrazin-2-yl]methanol Chemical group N[C@@H]1[C@@H](OCC11CCN(CC1)C=1C(=NC(=C(N=1)C)C1=C(C(=CC=C1)Cl)Cl)CO)C IKUYEYLZXGGCRD-ORAYPTAESA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 229940125528 allosteric inhibitor Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 230000001908 autoinhibitory effect Effects 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- RROBIDXNTUAHFW-UHFFFAOYSA-N benzotriazol-1-yloxy-tris(dimethylamino)phosphanium Chemical compound C1=CC=C2N(O[P+](N(C)C)(N(C)C)N(C)C)N=NC2=C1 RROBIDXNTUAHFW-UHFFFAOYSA-N 0.000 description 1
- GPRLTFBKWDERLU-UHFFFAOYSA-N bicyclo[2.2.2]octane Chemical compound C1CC2CCC1CC2 GPRLTFBKWDERLU-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N butyric aldehyde Natural products CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000013043 cell viability test Methods 0.000 description 1
- PBAYDYUZOSNJGU-UHFFFAOYSA-N chelidonic acid Natural products OC(=O)C1=CC(=O)C=C(C(O)=O)O1 PBAYDYUZOSNJGU-UHFFFAOYSA-N 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 238000003271 compound fluorescence assay Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 102000044858 human PTPN11 Human genes 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 description 1
- LPEKGGXMPWTOCB-VKHMYHEASA-N methyl (S)-lactate Chemical compound COC(=O)[C@H](C)O LPEKGGXMPWTOCB-VKHMYHEASA-N 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- YZMHQCWXYHARLS-UHFFFAOYSA-N naphthalene-1,2-disulfonic acid Chemical compound C1=CC=CC2=C(S(O)(=O)=O)C(S(=O)(=O)O)=CC=C21 YZMHQCWXYHARLS-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- LAIZPRYFQUWUBN-UHFFFAOYSA-L nickel chloride hexahydrate Chemical compound O.O.O.O.O.O.[Cl-].[Cl-].[Ni+2] LAIZPRYFQUWUBN-UHFFFAOYSA-L 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- YLACRFYIUQZNIV-UHFFFAOYSA-N o-(2,4-dinitrophenyl)hydroxylamine Chemical compound NOC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O YLACRFYIUQZNIV-UHFFFAOYSA-N 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- LJCNRYVRMXRIQR-OLXYHTOASA-L potassium sodium L-tartrate Chemical compound [Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O LJCNRYVRMXRIQR-OLXYHTOASA-L 0.000 description 1
- 229940074439 potassium sodium tartrate Drugs 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 238000004237 preparative chromatography Methods 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 235000011006 sodium potassium tartrate Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical class [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- LBJQKYPPYSCCBH-UHFFFAOYSA-N spiro[3.3]heptane Chemical compound C1CCC21CCC2 LBJQKYPPYSCCBH-UHFFFAOYSA-N 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- DORRAJSJCALZIB-VUWPPUDQSA-N tert-butyl (3S)-4-hydroxy-3-methyl-2-oxa-8-azaspiro[4.5]decane-8-carboxylate Chemical compound OC1[C@@H](OCC11CCN(CC1)C(=O)OC(C)(C)C)C DORRAJSJCALZIB-VUWPPUDQSA-N 0.000 description 1
- ZHHCNYQSLINMTK-KTTFQHEFSA-N tert-butyl (3S,4S)-4-[[(R)-tert-butylsulfinyl]amino]-3-methyl-2-oxa-8-azaspiro[4.5]decane-8-carboxylate Chemical compound CC(C)([S@@](=O)N[C@@H]1[C@@H](OCC11CCN(CC1)C(=O)OC(C)(C)C)C)C ZHHCNYQSLINMTK-KTTFQHEFSA-N 0.000 description 1
- NINPBWKLSQKRJE-UHFFFAOYSA-N tert-butyl 4-hydroxy-2-oxa-8-azaspiro[4.5]decane-8-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC11C(O)COC1 NINPBWKLSQKRJE-UHFFFAOYSA-N 0.000 description 1
- DRDVJQOGFWAVLH-UHFFFAOYSA-N tert-butyl n-hydroxycarbamate Chemical compound CC(C)(C)OC(=O)NO DRDVJQOGFWAVLH-UHFFFAOYSA-N 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical group C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Definitions
- the present invention relates to a novel pyrimidine-4(3H)-one heterocyclic compound or a pharmaceutically acceptable salt thereof that regulates or inhibits the activity of SHP2, a pharmaceutical composition containing the compound or a pharmaceutically acceptable salt thereof, and
- the method for preparing the compound or its pharmaceutically acceptable salt and the compound or its pharmaceutically acceptable salt or a pharmaceutical composition containing the compound or its pharmaceutically acceptable salt are prepared for the treatment and/or prevention of SHP2
- SHP2 (Src Homology 2 domain-containing Phosphatase 2) is a non-receptor protein tyrosine phosphatase encoded by the PTPN11 (Protein Tyrosine Phosphatase Nonreceptor type 11) gene.
- SHP2 contains two SH2 domains (Src Homology domain), a PTP domain (Protein Tyrosine Phosphatase domain) and a C-terminal tail. Under normal conditions, SHP2 is in a self-inhibitory conformation, and its N-SH2 binds to PTP, blocking the substrate channel at the catalytic site of PTP, thereby inhibiting the activity of PTP.
- SH2 binds to bisphosphotyrosine peptides (such as IRS-1)
- the autoinhibitory interaction of SH2-PTP is released, PTP catalytic sites are exposed, SHP2 is activated, and tyrosine dephosphorylation is catalyzed reaction.
- SHP2 is widely expressed. As an oncogene, it mediates the activation of a variety of cancer-causing signal transduction channels, such as the RAS-ERK, PI3K-AKT and JAK-STAT pathways, and promotes the survival and proliferation of cancer cells. SHP2 can bind to and dephosphorylate RAS, increase RAS-RAF association, and activate downstream cell proliferation signals. SHP2 also mediates the compensatory activation pathway after MEK and other kinases are inhibited, thereby promoting tumor resistance (Ruess DA, et al., Nat. Med. 2018, 24, 954-960). Therefore, the activation of SHP2 is closely related to the occurrence of many diseases, such as leukemia, melanoma, breast cancer, lung cancer, colon cancer, neuroblastoma, hepatocellular carcinoma and so on.
- diseases such as leukemia, melanoma, breast cancer, lung cancer, colon cancer, neuroblastoma, hepatocellular carcinoma and so on.
- SHP2 also plays an important role in the immune checkpoint channel of PD-1 and BTLA (B-and T-Lymphocyte Attenuator), not only inhibiting T-cell activation but also promoting T-cell disability (Li J, et al., Cancer Res. 2015, 75, 508-518).
- SHP2 As an anti-tumor target, SHP2 has attracted a lot of attention.
- the SHP2 catalytic site inhibitor Due to the high protein sequence homology of the PTP catalytic site and the high hydrophilicity of the PTP catalytic pocket, the SHP2 catalytic site inhibitor has poor selectivity, poor cell permeability, and low bioavailability.
- the discovery of Novartis allosteric inhibitor SHP099 (Chen Y, et al., Nature 2016, 535, 148-52) provides a new channel for the development of highly specific oral SHP2 inhibitors.
- many companies have published some patent applications for SHP2 inhibitors, including WO2015107495, WO2016203405, WO2018057884, WO2018013597, WO2017211303, etc.
- the present invention designs a compound having a structure represented by the general formula (I), and finds that the compound having such a structure exhibits an excellent SHP2 activity inhibitory effect.
- the present invention provides a compound represented by general formula (I) or its prodrugs, stable isotope derivatives, pharmaceutically acceptable salts, isomers and mixtures thereof as SHP2 inhibitors:
- Ring A is a benzene ring or a 6-membered heteroaromatic ring
- ring B is a 5-membered heteroaromatic ring fused with ring A.
- the benzene ring and heteroaromatic ring are optionally selected from D, halogen, and cyano.
- R 1 is H, D, cyano, C 1-2 alkyl, cyclopropyl, -OR a , -NR a R b or -C(O)NR a R b , the alkyl and cyclopropyl
- One or more hydrogens are optionally substituted by one or more D or fluorine;
- R 2 is H, C 1-2 alkyl or cyclopropyl, one or more hydrogens of said alkyl and cyclopropyl are optionally substituted by one or more selected from D, fluorine or hydroxyl;
- R 4a and R 4b are each independently selected from H, D, halo, cyano, -OR a, -NR a R b , -C (O) R a, -C (O) NR a R b, C 1- 6 alkyl group, C 3-6 cycloalkyl group, 4-7 membered heterocyclic group or 5-6 membered heteroaryl group, but R 4a and R 4b cannot be cyano, -OR a or -NR a R b at the same time,
- the alkyl group, cycloalkyl group, heterocyclic group and heteroaryl group are optionally selected by one or more selected from D, halogen, cyano, oxo, C 1-6 alkyl, C 3-6 cycloalkyl, 4-7 membered heterocyclic group, 5-6 membered heteroaryl group, -OR a , -NR a R b , -C(O)R a or -C(
- R 5a , R 5b , R 6a and R 6b are each independently selected from H, D, fluorine or methyl;
- R a and R b are each independently selected from H, C 1-6 alkyl, C 3-6 cycloalkyl or 4-7 membered heterocyclic group, said alkyl, cycloalkyl and heterocyclic group are optionally selected by One or more substituents selected from D, fluorine, cyano, oxo, hydroxyl, -OCH 3 or -NH 2 are substituted.
- One embodiment of the present invention relates to the compound represented by the above general formula (I) or its pharmaceutically acceptable salts, prodrugs, stable isotope derivatives, isomers and mixtures thereof, which are described in the general formula (II)
- Ring A is a benzene ring or a 6-membered heteroaromatic ring
- ring B is a 5-membered heteroaromatic ring fused with ring A.
- the benzene ring and heteroaromatic ring are optionally selected from D, halogen, and cyano.
- R 1 is H, D, cyano, C 1-2 alkyl, -OR a or -NR a R b , and one or more hydrogens of the alkyl group are optionally substituted by one or more D or fluorine;
- R 2 is H or C 1-2 alkyl, one or more hydrogens of the alkyl are optionally substituted by one or more D or fluorine;
- R 4a and R 4b are each independently selected from H, D, halogen, cyano, -OR a , -NR a R b , -C(O)NR a R b , C 1-6 alkyl, C 3-6 Cycloalkyl, 4-7 membered heterocyclic group or 5-6 membered heteroaryl, but R 4a and R 4b cannot be cyano, -OR a or -NR a R b at the same time, the alkyl, cycloalkyl , Heterocyclyl and heteroaryl are optionally selected by one or more selected from D, halogen, cyano, oxo, C 1-6 alkyl, C 3-6 cycloalkyl, 4-7 membered heterocyclyl, 5-6 membered heteroaryl, -OR a , -NR a R b , -C(O)R a or -C(O)NR a R b substituents; R 4a and
- R a and R b are each independently selected from H, C 1-6 alkyl, C 3-6 cycloalkyl or 4-7 membered heterocyclic group, said alkyl, cycloalkyl and heterocyclic group are optionally selected by One or more substituents selected from D, fluorine, cyano, oxo, hydroxyl, -OCH 3 or -NH 2 are substituted.
- Another embodiment of the present invention relates to the compound represented by the above general formula (I) or its pharmaceutically acceptable salts, prodrugs, stable isotope derivatives, isomers and mixtures thereof, which are represented by the general formula (III)
- Ring A is a benzene ring or a 6-membered heteroaromatic ring
- ring B is a 5-membered heteroaromatic ring fused with ring A.
- the benzene ring and heteroaromatic ring are optionally selected from D, halogen, and cyano.
- X is -O- or -CR 8a R 8b -;
- R 1 is H, D, cyano, C 1-2 alkyl or -NR a R b , and one or more hydrogens of the alkyl group are optionally substituted by one or more D or fluorine;
- R 2 is H or C 1-2 alkyl, one or more hydrogens of the alkyl are optionally substituted by one or more D or fluorine;
- R 7a , R 7b , R 8a , R 8b , R 9a and R 9b are each independently selected from H, D, halogen, cyano, C 1-2 alkyl or -OR c , one or more of the alkyl groups Each hydrogen is optionally substituted by one or more selected from D, fluorine or hydroxyl, but R 7a and R 7a , R 8a and R 8b , R 9a and R 9b optionally cannot be -OR c at the same time;
- R a and R b are each independently selected from H, C 1-6 alkyl, C 3-6 cycloalkyl or 4-7 membered heterocyclic group, said alkyl, cycloalkyl and heterocyclic group are optionally selected by One or more substituents selected from D, fluorine, cyano, oxo, hydroxyl, -OCH 3 or -NH 2 ;
- R c is H or C 1-2 alkyl, and one or more hydrogens of the alkyl are optionally substituted by one or more D or fluorine.
- Another embodiment of the present invention relates to the compound represented by the above general formula (I) or its pharmaceutically acceptable salts, prodrugs, stable isotope derivatives, isomers and mixtures thereof, which are represented by the general formula (IV)
- Ring A is a benzene ring or a 6-membered heteroaromatic ring
- ring B is a 5-membered heteroaromatic ring fused with ring A.
- the benzene ring and heteroaromatic ring are optionally selected from D, halogen, and cyano. , Oxo, C 1-2 alkyl, -OR a or -NR a R b substituents, wherein one or more hydrogens of the alkyl group are optionally substituted by one or more D or fluorine;
- X is -O- or -CH 2 -;
- R 1 is independently selected from H, D, C 1-2 alkyl or -NR a R b , one or more hydrogens of the alkyl group are optionally substituted by one or more D or fluorine;
- R 2 is H or a C 1-2 alkyl group, one or more hydrogens of the alkyl group are optionally substituted by one or more D or fluorine;
- R 7 is H, D or C 1-2 alkyl, one or more hydrogens of said alkyl are optionally substituted by one or more D or fluorine;
- R a and R b are each independently H or C 1-2 alkyl, and one or more hydrogens of the alkyl group are optionally substituted with one or more D or fluorine.
- the present invention further relates to the compound represented by the above general formula (I), wherein the compound is selected from:
- the compound of the present invention can effectively inhibit the activity of SHP2, and preferably has an IC 50 of less than 50 nM.
- the compound of the present invention has a significant inhibitory effect on the proliferation of NCI-H358 cells, and preferably its IC 50 is less than 1000 nM.
- Another aspect of the present invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising a compound represented by general formula (I) or a pharmaceutically acceptable salt, prodrug, stable isotope derivative, isomer and mixture thereof Forms and pharmaceutically acceptable carriers and excipients.
- the present invention further relates to a pharmaceutical composition
- a pharmaceutical composition comprising a compound represented by the general formula (I) or a pharmaceutically acceptable salt, prodrug, stable isotope derivative, isomer and mixture thereof, and at least An additional drug, wherein the at least one additional drug includes, but is not limited to, chemotherapeutic drugs, targeted drugs, DNA synthesis inhibitors, antibody drugs, antibody drug conjugates, anti-tumor drugs, immunosuppressants, and the like.
- Another aspect of the present invention also relates to the compound represented by the general formula (I) or its pharmaceutically acceptable salts, prodrugs, stable isotope derivatives, isomers and mixtures thereof, or the pharmaceutical composition in the preparation of medicines
- the drug is used to treat or prevent SHP2-mediated related diseases, wherein the diseases include but are not limited to leukemia, Noonan syndrome, leopard spot syndrome, neuroblastoma, lung cancer, breast cancer, colon cancer , Esophageal cancer, stomach cancer, head and neck cancer, etc.
- the drug can be in any pharmaceutical dosage form, including but not limited to tablets, capsules, solutions, freeze-dried preparations, injections and the like.
- the pharmaceutical preparation of the present invention can be administered in the form of a dosage unit containing a predetermined amount of active ingredient per dosage unit.
- a dosage unit may contain, for example, 0.5 mg to 1 g, preferably 1 mg to 700 mg, and particularly preferably 5 mg to 500 mg of the compound of the present invention according to the condition to be treated, the method of administration, and the age, weight and condition of the patient.
- methods known in the pharmaceutical field can be used to prepare this type of pharmaceutical preparations, such as mixing the active ingredient with one or more excipients and/or adjuvants.
- compositions of the present invention may be suitable for administration by any desired suitable method, such as oral (including oral or sublingual), rectal, nasal, topical (including oral, sublingual or transdermal), vaginal or parenteral (Including subcutaneous, intramuscular, intravenous or intradermal) method of administration.
- oral including oral or sublingual
- rectal including oral or sublingual
- nasal including oral, sublingual or transdermal
- vaginal or parenteral including subcutaneous, intramuscular, intravenous or intradermal
- C xy means the range of carbon atoms, where x and y are both integers, for example, C 3-8 cycloalkyl means a cycloalkyl group with 3-8 carbon atoms, that is, with 3, 4, 5, 6, Cycloalkyl groups of 7 or 8 carbon atoms. It should also be understood that “C 3-8 "also includes any sub-range therein, such as C 3-7 , C 3 6 , C 4-7 , C 4-6 , C 5-6 and the like.
- Alkyl refers to a saturated linear or branched hydrocarbon group containing 1 to 20 carbon atoms, for example, 1 to 8 carbon atoms, 1 to 6 carbon atoms, or 1 to 4 carbon atoms.
- alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl Group, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl -2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-Dimethylbutyl, 2-ethylbutyl, etc.
- Cycloalkyl or carbocyclic refers to a saturated cyclic hydrocarbyl substituent containing 3 to 14 carbon ring atoms.
- the cycloalkyl group may be a single carbon ring, and usually contains 3 to 8, 3 to 7, or 3 to 6 carbon ring atoms.
- Non-limiting examples of monocyclic cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and the like.
- Cycloalkyl groups can also be fused, bridged or spiro-bonded bi- or tricyclic rings, such as decahydronaphthyl, bicyclo[2.2.2]octane, spiro[3.3]heptane and the like.
- Heterocyclic group or heterocyclic ring refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic group, which includes 3 to 20 ring atoms, for example, 3 to 14, 3 to 12, 3 to 10 1, 3 to 8, 3 to 6, or 5 to 6 ring atoms, of which one or more ring atoms are selected from nitrogen, oxygen or S(O) m (where m is an integer from 0 to 2), but does not include The ring part of -OO-, -OS- or -SS-, and the remaining ring atoms are carbon.
- It preferably includes 3 to 12 ring atoms, more preferably 3 to 10 ring atoms, more preferably 4 to 7 ring atoms, more preferably 4 to 6 ring atoms, most preferably 5 or 6 ring atoms, of which 1 to 4 It is a heteroatom, more preferably 1 to 3 are heteroatoms, and most preferably 1 to 2 are heteroatoms.
- Non-limiting examples of monocyclic heterocyclic groups include pyrrolidinyl, oxbutanyl, piperidinyl, piperazinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiopyranyl, morpholinyl, thiomorphyl Linyl, homopiperazinyl, azetidine, etc.
- Polycyclic heterocyclic groups include fused, bridged or spiro heterocyclic groups, such as octahydrocyclopenta[c]pyrrole, octahydropyrrolo[1,2-a]pyrazine, 3,8- Diazabicyclo[3.2.1]octane, 5-azaspiro[2.4]heptane, 2-oxa-7-azaspiro[3.5]nonane, etc.
- Aryl or aromatic ring refers to an aromatic monocyclic or condensed polycyclic group containing 6 to 14 carbon atoms, preferably 6 to 10 members, such as phenyl and naphthyl, and most preferably phenyl.
- the aryl ring may be fused to a heteroaryl, heterocyclic or cycloalkyl ring, wherein the ring connected to the parent structure is an aryl ring.
- Non-limiting examples include:
- Heteroaryl or heteroaromatic ring refers to a heteroaromatic system containing 5 to 14 ring atoms, where 1 to 4 ring atoms are selected from heteroatoms including oxygen, sulfur, and nitrogen. Heteroaryl is preferably 5 to 10 members, more preferably heteroaryl is 5 or 6 members, such as furyl, thienyl, pyridyl, pyrrolyl, pyrimidinyl, pyrazinyl, pyrazolyl, imidazolyl, tetrakis Azolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, quinolinyl, isoquinolinyl, indolyl, isoindolyl and the like.
- the heteroaryl ring may be fused to an aryl, heterocyclic or cycloalkyl ring, wherein the ring connected to the parent structure is a heteroaryl ring. Non-limiting examples
- Halogen refers to fluorine, chlorine, bromine or iodine.
- Cyano refers to -CN.
- heterocyclic group optionally substituted by an alkyl group means that an alkyl group may but need not be present, and the expression includes the case where the heterocyclic group is substituted by an alkyl group and the case where the heterocyclic group is not substituted by an alkyl group.
- substitution means that one or more hydrogen atoms in the group, preferably 5, more preferably 1 to 3 hydrogen atoms are independently substituted with a corresponding number of substituents. It goes without saying that the substituents are only in their possible chemical positions, and those skilled in the art can determine (by experiment or theory) possible or impossible substitutions without too much effort. For example, an amino group or a hydroxyl group having free hydrogen may be unstable when combined with a carbon atom having an unsaturated (e.g., olefinic) bond.
- the substituents include, but are not limited to, halogen, cyano, nitro, oxo, -SF 5 , C 1-4 alkyl, C 3-7 cycloalkyl, 4-7 membered heterocyclic group, phenyl, 5 -6-membered heteroaryl and so on.
- “Isomers” refer to compounds that have the same molecular formula but differ in the nature or sequence of bonding of their atoms or the arrangement of their atoms in space. Isomers that differ in the arrangement of their atoms in space are called “stereoisomers”. Stereoisomers include optical isomers, geometric isomers and conformational isomers.
- the compounds of the present invention may exist in the form of optical isomers.
- Optical isomers include enantiomers and diastereomers.
- Enantiomers means that two stereoisomers are mirror images of each other but not superimposable with each other.
- a racemic mixture or racemate refers to a mixture of equal numbers of left and right enantiomers of a chiral molecule.
- Diastereoisomers means that two stereoisomers are not mirror images of each other and cannot be superimposed.
- optical isomer When the optical isomer is a single isomer and its absolute configuration is determined, it is the absolute configuration of "R” or “S” according to the configuration of the substituent on the chiral carbon atom; when the absolute configuration of the optical isomer The configuration is not determined, and it is (+) or (-) according to the measured optical rotation value.
- Methods of preparing and separating optical isomers are known in the art.
- the compounds of the present invention may also exist in geometric isomers.
- the present invention considers various geometric isomers and mixtures thereof resulting from the distribution of substituents around carbon-carbon double bonds, carbon-nitrogen double bonds, cycloalkyl or heterocyclic groups. Substituents around a carbon-carbon double bond or carbon-nitrogen bond are designated as Z or E configuration, and substituents around a cycloalkyl or heterocyclic ring are designated as cis or trans configuration.
- the compounds of the present invention may also exhibit tautomerism, such as keto-enol tautomerism.
- the present invention includes any tautomeric or stereoisomeric forms and mixtures thereof, and is not limited to any one of the tautomeric or stereoisomeric forms used in the naming or chemical structural formula of the compound.
- isotopes refer to all isotopes of atoms occurring in the compounds of the present invention. Isotopes include those atoms that have the same atomic number but different mass numbers. Examples of isotopes suitable for incorporation into the compounds of the present invention are hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine and chlorine, such as but not limited to 2 H(D), 3 H, 13 C, 14 C, 15 N, respectively , 17 O, 18 O, 31 P, 32 P, 35 S, 18 F and 36 Cl.
- the isotope-labeled compounds of the present invention can generally be prepared by conventional techniques known to those skilled in the art or by methods similar to those described in the appended examples using appropriate isotope-labeled reagents instead of non-isotopically-labeled reagents. Such compounds have various potential uses, for example as standards and reagents in the determination of biological activity. In the case of stable isotopes, such compounds have the potential to advantageously alter biological, pharmacological or pharmacokinetic properties.
- Deuterium (D) is a preferred isotope of the present invention. For example, hydrogen in methyl, methylene or methine can be replaced by deuterium.
- the compounds of the present invention can be administered in the form of prodrugs.
- Prodrug refers to a derivative of the biologically active compound of the invention that is converted into a derivative of the biologically active compound of the present invention under physiological conditions in the living body, for example, by oxidation, reduction, hydrolysis, etc. (each of them utilizes enzymes or is performed without the participation of enzymes).
- prodrugs are compounds in which the amino group in the compound of the present invention is acylated, alkylated or phosphorylated, such as eicosanoylamino, alanylamino, pivaloyloxymethylamino, or
- the hydroxyl group is acylated, alkylated, phosphorylated or converted into borate, such as acetoxy, palmitoyloxy, pivaloyloxy, succinyloxy, fumaryloxy, alanyloxy Or wherein the carboxyl group is esterified or amidated, or wherein the sulfhydryl group forms a disulfide bridge with a carrier molecule, such as a peptide, that selectively delivers the drug to the target and/or to the cytosol of the cell.
- a carrier molecule such as a peptide
- “Pharmaceutically acceptable salt” or “pharmaceutically acceptable salt” refers to salts made from pharmaceutically acceptable bases or acids, including inorganic bases or acids and organic bases or acids.
- the present invention also includes their corresponding pharmaceutically acceptable salts. Therefore, the compounds of the invention containing acidic groups can exist in the form of salts and can be used in accordance with the invention, for example as alkali metal salts, alkaline earth metal salts or as ammonium salts. More specific examples of such salts include sodium, potassium, calcium, magnesium, or salts with ammonia or organic amines, such as ethylamine, ethanolamine, triethanolamine, or amino acids.
- the compounds of the present invention containing basic groups can exist in the form of salts and can be used in the form of their addition salts with inorganic or organic acids according to the present invention.
- suitable acids include hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, nitric acid, methanesulfonic acid, p-toluenesulfonic acid, naphthalenedisulfonic acid, oxalic acid, acetic acid, tartaric acid, lactic acid, salicylic acid, benzoic acid, formic acid, propylene Acid, pivalic acid, malonic acid, succinic acid, pimelic acid, fumaric acid, maleic acid, malic acid, sulfamic acid, phenylpropionic acid, gluconic acid, ascorbic acid, isonicotinic acid, citric acid, Adipic acid and other acids known to those skilled in the art.
- the present invention also includes internal salts or betaines in addition to the salt forms mentioned.
- Each salt can be obtained by conventional methods known to those skilled in the art, for example, by contacting these with organic or inorganic acids or bases in a solvent or dispersant or by anion exchange or cation exchange with other salts.
- “Pharmaceutical composition” refers to containing one or more of the compounds described herein or their pharmaceutically acceptable salts, prodrugs, stable isotope derivatives, isomers and mixtures thereof, and other components such as pharmaceutically acceptable carriers And excipients.
- the purpose of the pharmaceutical composition is to promote the administration to the organism, which is beneficial to the absorption of the active ingredient and thus the biological activity.
- terapéuticaally effective amount refers to the amount of the compound of the present invention that can effectively inhibit the function of SHP2 and/or treat or prevent the disease.
- patient refers to mammals, especially humans.
- the present invention also provides a method for preparing the compound.
- the preparation of the compound of the general formula (I) of the present invention can be accomplished by the following exemplary methods and examples, but these methods and examples should not be considered as limiting the scope of the present invention in any way.
- the compounds of the present invention can also be synthesized by synthetic techniques known to those skilled in the art, or a combination of methods known in the art and the methods of the present invention can be used.
- the product obtained in each step of the reaction is obtained by separation techniques known in the art, including but not limited to extraction, filtration, distillation, crystallization, chromatographic separation and the like.
- the starting materials and chemical reagents required for synthesis can be conventionally synthesized or purchased according to literature (available on SciFinder).
- the heterocyclic compound of the general formula (I) of the present invention can be synthesized according to the route described in Method A: 1) A1 is substituted with NH in piperidine compound A2 under base catalysis or condensation reaction with a condensing agent to obtain an intermediate A3; 2) A3 then reacts with the sulfhydryl group on the 5,6-fused heteroaromatic ring through Buchwald coupling reaction to produce the product A4.
- the type of heterocyclic compounds described by the general formula (I) of the present invention can be synthesized according to the route described in Method B: 1) A1 and A2a undergo substitution reaction under base catalysis or condensation reaction with a condensing agent to obtain intermediate A3a; 2) The ketone group in A3a and (R)-2-methylpropane-2-sulfinamide undergo reductive amination to form A5a; 3) A5a and the sulfhydryl group on the 5,6-fused heteroaromatic ring are formed by Buchwald coupling reaction A6a; 4) A6a is deprotected in an acidic environment to obtain product A4a.
- the starting materials of the present invention can be synthesized by or according to methods known in the art, or can be purchased from ABCR GmbH & Co. KG, Acros Organics, Aldrich Chemical Company, Accela ChemBio Inc., Beijing Coupling Chemicals And other chemical companies.
- the structure of the compound is determined by nuclear magnetic resonance (NMR) or mass spectrometry (MS).
- NMR nuclear magnetic resonance
- MS mass spectrometry
- DMSO-d 6 deuterated dimethyl sulfoxide
- CDC1 3 deuterated chloroform
- CD 3 OD deuterated methanol
- the internal standard is Tetramethylsilane (TMS)
- TMS Tetramethylsilane
- ESI Agilent SQD mass spectrometer
- HPLC uses Agilent 1260DAD high pressure liquid chromatograph (Poroshell120EC-C18, 50 ⁇ 3.0mm, 2.7 ⁇ m column) or Waters Arc high pressure liquid chromatograph (Sunfire C18, 150 ⁇ 4.6mm, 5 ⁇ m column).
- reaction temperature is room temperature (20-30°C).
- the reactions are all carried out under an argon atmosphere or a nitrogen atmosphere.
- the argon atmosphere or nitrogen atmosphere means that the reaction flask is connected to an argon or nitrogen balloon with a volume of about 1L.
- the hydrogen atmosphere means that the reaction flask is evacuated and then filled with hydrogen (repeated 3 times), and then a hydrogen balloon with a volume of about 1L is connected.
- the microwave reaction uses a CEM Discover-SP type microwave reactor.
- the monitoring of the reaction process in the examples uses Agilent liquid mass spectrometry (1260/6120), or thin layer chromatography (TLC), and the thickness of the silica gel plate used is 0.15-0.2 mm (Qingdao Ocean GF254).
- the compound is purified by column chromatography or thin layer chromatography, wherein the column chromatography uses Qingdao Ocean’s 200-300 mesh silica gel, and the thin layer chromatography uses Qingdao Ocean’s GF254 silica gel plate with a thickness of 0.4 to 0.5 mm.
- Column chromatography or thin layer chromatography developing solvent system usually has a) dichloromethane and methanol system, b) petroleum ether and ethyl acetate system, or as shown in the examples.
- the volume ratio of the solvent is adjusted according to the polarity of the compound, and a small amount of triethylamine or other acidic or alkaline reagents can also be added for further adjustment.
- the purification of the compound also used Waters mass spectrometry guided automatic preparation system (mass detector: SQD2), according to the polarity of the compound, an appropriate acetonitrile/water (containing 0.1% trifluoroacetic acid or formic acid, or 0.05% ammonia) gradient was used in 20mL/ The flow rate of min was used to elute the reversed-phase high pressure column (XBridge-C18, 19 ⁇ 150mm, 5 ⁇ m).
- 1N diluted hydrochloric acid can be added after purification using an automatic preparation system, and then the solvent can be removed under reduced pressure to obtain hydrochloride.
- DMF refers to N,N-dimethylformamide
- DIPEA N,N-diisopropylethylamine
- DBU refers to 1,8-diazabicyclo[5.4.0]undec-7-ene.
- NBS N-bromosuccinimide
- NIS refers to N-iodosuccinimide.
- XantPhos refers to 4,5-bis(diphenylphosphine)-9,9-dimethylxanthene.
- the abbreviation Pd 2 (dba) 3 refers to tris(dibenzylideneacetone)dipalladium.
- Carter condensing agent refers to benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate.
- 2,4-Dichloro-5-iodopyrimidine 1a (8.0g, 29.1mmol) was dissolved in tetrahydrofuran (100mL), sodium hydroxide solution (1N, 45mL) was added at 0°C, the reaction mixture was warmed to room temperature and stirred for 16 hours .
- the pH was adjusted to acidity with citric acid, and extraction was performed with ethyl acetate (60 mL ⁇ 3).
- the organic phases were combined and washed with saturated brine (30 mL ⁇ 3), dried over anhydrous sodium sulfate, and dissolved under reduced pressure to obtain the target product 1b (6.7 g, solid), yield: 91%.
- a methanol solution (30%, 158 mg, 0.88 mmol) of sodium methoxide (30%, 158 mg, 0.88 mmol) was added to a methanol (20 mL) solution of 1 g (200 mg, 0.8 mmol), and the mixture was stirred at room temperature for 2 hours. Solubility was removed under reduced pressure to obtain the target product for 1 h (100 mg, solid), with a yield of 73%. The product was used directly in the next reaction without purification.
- the organic phase was dried with anhydrous sodium sulfate, filtered to remove the desiccant, and the solvent was removed under reduced pressure.
- Potassium tert-butoxide (204 mg, 1.82 mmol) was added to the solution of 2b (240 mg, 0.91 mmol) in tetrahydrofuran (5 mL), and the mixture was stirred at room temperature for 2 hours. It was acidified to pH 4 with hydrochloric acid (6N), and extracted with ethyl acetate (20 mL). The organic phase was dried with anhydrous sodium sulfate, filtered to remove the desiccant, and desolventized under reduced pressure to obtain the target product 2c (130 mg, solid), yield: 87%.
- a methanol solution (30%, 443.5 mg, 2.46 mmol) of sodium methoxide (30%, 443.5 mg, 2.46 mmol) was added to a methanol (20 mL) solution of 3b (560 mg, 2.24 mmol), and the mixture was stirred at 30°C for 1 hour. Solubility was removed under reduced pressure to obtain the target product 3c (200 mg, solid), yield: 51%. The product was used directly in the next reaction without purification.
- a methanol solution (30%, 182 mg, 1.01 mmol) of sodium methoxide (30%, 182 mg, 1.01 mmol) was added to a methanol (20 mL) solution of 4d (230 mg, 0.92 mmol), and the mixture was stirred at 30°C for 4 hours. The solvent was removed under reduced pressure to obtain the target product 4e (150 mg, solid), with a yield of 95%. The product was used directly in the next reaction without purification.
- a methanol solution (30%, 317 mg, 1.76 mmol) of sodium methoxide (30%, 317 mg, 1.76 mmol) was added to a methanol (20 mL) solution of 5b (400 mg, 1.6 mmol), and the mixture was stirred at room temperature for 2 hours.
- the reaction mixture was poured into water (100 mL), the pH was adjusted to weakly acidic with citric acid, and extracted with ethyl acetate (30 mL ⁇ 3).
- the organic phases were combined and washed with saturated brine (20 mL ⁇ 3), dried over anhydrous sodium sulfate, filtered to remove the desiccant, and dissolved under reduced pressure.
- Potassium tert-butoxide (672 mg, 6.0 mmol) was added to the solution of 6b (500 mg, 2.0 mmol) in tetrahydrofuran (10 mL), and the mixture was stirred at room temperature for 2 hours. It was acidified to pH 4 with hydrochloric acid (6N) and extracted with dichloromethane (20 mL). The organic phase was dried with anhydrous sodium sulfate, filtered to remove the desiccant, and dissolved under reduced pressure to obtain the target product 6c (300 mg, solid), yield: 100%.
- Trimethyloxonium tetrafluoroborate (733 mg, 4.95 mmol) was added to a solution of 7b (760 mg, 3.3 mmol) in ethyl acetate (15 mL) under ice cooling, and the reaction mixture was stirred at room temperature for 4 hours. Add petroleum ether (30 mL) to dilute, stir for 10 minutes, and filter. The filtrate was added with ethyl acetate (20 mL), and washed with sodium bicarbonate solution (30 mL ⁇ 3) and saturated brine (20 mL ⁇ 3).
- a methanol solution (30%, 93 mg, 0.52 mmol) of sodium methoxide (30%, 93 mg, 0.52 mmol) was added to a methanol (20 mL) solution of 7d (140 mg, 0.47 mmol), and the mixture was stirred at 30°C for 32 hours. The solvent was removed under reduced pressure to obtain the target product 7e (100 mg, solid), with a yield of 96%. The product was used directly in the next reaction without purification.
- a methanol solution (30%, 45.5 mg, 0.25 mmol) of sodium methoxide (30%, 45.5 mg, 0.25 mmol) was added to a methanol (3 mL) solution of 8 g (60 mg, 0.21 mmol), and the mixture was stirred at 30°C for 4 hours. Solubility was removed under reduced pressure to obtain the target product for 8h (40 mg, solid), yield: 92%. The product was directly used in the next reaction without purification.
- a methanol solution (30%, 130 mg, 0.72 mmol) of sodium methoxide (30%, 130 mg, 0.72 mmol) was added to a methanol (20 mL) solution of 9d (195 mg, 0.60 mmol), and the mixture was stirred at 30°C for 16 hours. The solvent was removed under reduced pressure to obtain the target product 9e (220 mg, solid, crude product). The product was used directly in the next reaction without purification.
- Oxalyl chloride (27.6 g, 218.9 mmol) was added dropwise to dichloromethane (500 mL) at -30°C, the temperature was lowered to -78°C, and dimethyl sulfoxide (21.7 g, 278.6 mmol) was added dropwise. After the reaction mixture was stirred at -78°C for 30 minutes, a solution of 10b (35 g, 199 mmol) in dichloromethane (100 mL) was slowly added and stirred for 1 hour. Triethylamine (100.5g, 995mmol) was added dropwise, stirring was continued at -78°C for 30 minutes, and then stirred at room temperature overnight.
- a tetrahydrofuran solution (1M, 193 mL, 193 mmol) of tetrabutylammonium fluoride (1M, 193 mL, 193 mmol) was added to a tetrahydrofuran (400 mL) solution of 10e (55 g, 128.5 mmol), and the mixture was stirred at room temperature for 2 hours.
- Dilute with saturated sodium bicarbonate solution and water (100 mL, 1/2 v/v) add ethyl acetate (200 mL), separate the layers, and extract the aqueous phase with ethyl acetate (200 mL ⁇ 3).
- the reaction mixture 10g (8.5g, 32.9mmol), Dess-Martin oxidant (27.4g, 64.56mmol) and dichloromethane (200mL) were stirred at 0°C for 2 hours.
- Saturated sodium bicarbonate solution and saturated sodium thiosulfate solution (100mL, 1/1v/v) were added, stirred vigorously, and separated.
- the aqueous phase was extracted with dichloromethane (200 mL ⁇ 3).
- the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure.
- reaction mixture 10j (60mg, 0.15mmol), (R)-2-methylpropane-2-sulfinamide (36.3mg, 0.3mmol), tetraethyl titanate (137mg, 0.6mmol) and tetrahydrofuran (5mL) Heat to 90°C and stir for 4 hours. Cool to 0°C, add methanol (2 mL) and lithium borohydride in tetrahydrofuran (2.0M, 0.15 mL, 0.3 mmol), and stir for 1 hour. Water (5 mL) and dichloromethane (20 mL) were added, and the layers were separated. The aqueous phase was extracted with dichloromethane (10 mL ⁇ 3).
- the aqueous phase was extracted with dichloromethane (10 mL ⁇ 3), and the organic phases were combined and dried over anhydrous sodium sulfate, filtered, and dissolved under reduced pressure.
- a tetrahydrofuran solution (1M, 303 mL, 303 mmol) of tetrabutylammonium fluoride (1M, 303 mL, 303 mmol) was added to a solution of 11e (90 g, 223 mmol) in tetrahydrofuran (1300 mL), and the mixture was stirred at room temperature overnight.
- Dilute with saturated sodium bicarbonate solution and water (800 mL, 1/2 v/v) add ethyl acetate (800 mL), separate the layers, and extract the aqueous phase with ethyl acetate (500 mL ⁇ 3).
- Dissolve 12a (86 mg, 0.166 mmol) in methanol (5 mL), add a dioxane solution of hydrogen chloride (4.0 M, 1 mL), and stir at room temperature for 1 hour. Concentrated under reduced pressure, and the residue was purified by reverse-phase high performance liquid chromatography to obtain the target product 12 (16.8 mg, solid), yield: 19%.
- reaction mixture 1-benzyl-4-methylpiperidine-4-carbonitrile 16a (2g, 9.3mmol), di-tert-butyl dicarbonate (6.1g, 27.9mmol), nickel chloride hexahydrate (2.2g, 9.3 mmol) and methanol (50 mL) were stirred at room temperature for 15 minutes. Cool to 0°C, add sodium borohydride (1.77 g, 46.5 mmol), warm to room temperature, and stir for 8 hours. The solvent was removed under reduced pressure, and the residue was suspended in methylene chloride and filtered.
- reaction mixture 17c (180mg, 0.35mmol), 2c (70mg, 0.42mmol), DIPEA (135mg, 1.05mmol), Pd 2 (dba) 3 (32mg, 0.035mmol), XantPhos (20mg, 0.035mmol) and dioxygen
- Potassium tert-butoxide (224 mg, 2 mmol) was added to a solution of 1 g (250 mg, 1 mmol) in tetrahydrofuran (5 mL), and the mixture was stirred at room temperature for 2 hours. It was quenched with water and washed with ethyl acetate. The aqueous phase was acidified to pH 4 with hydrochloric acid (6N) and extracted with ethyl acetate. The organic phase was dried with anhydrous sodium sulfate, filtered to remove the desiccant, and dissolved under reduced pressure to obtain the target product 18a (100 mg, solid), yield: 67%.
- reaction mixture 17c (180mg, 0.35mmol), 18a (63mg, 0.42mmol), DIPEA (135mg, 1.05mmol), Pd 2 (dba) 3 (32mg, 0.035mmol), XantPhos (20mg, 0.035mmol) and dioxy
- Recombinant human SHP2 full-length protein was expressed and purified by Tsinghua University's protein purification and identification platform, and the double phosphorylated polypeptide (H2N-LN(pY)IDLDLV-(dPEG8)LST(pY)ASINFQK-amide) was synthesized by GenScript Biotechnology Co., Ltd.
- the alternative substrate DiFMUP was purchased from Thermo Fisher Scientific (Cat. No. D6567).
- the reaction buffer contains the following components: 60mM HEPES (pH 7.2), 75mM NaCl, 75mM KCl, 1mM EDTA, 0.05% TWEEN 20, and 5mM DTT.
- the compound was dissolved and diluted to 100 ⁇ M in DMSO (Sigma, product number D5879), and then serially diluted with DMSO to the lowest concentration of 6.1 nM by 4 times, and then diluted 25 times with reaction buffer at each concentration point.
- DMSO Sigma, product number D5879
- the fluorescence signal value is positively correlated with the degree of dephosphorylation of the substrate, which reflects the catalytic activity of SHP2 phosphatase.
- the experiment not added as 100% inhibition proteome group, but did not increase protein plus compound group group as 0% inhibition, compound using XLfit software drawing inhibition curves and calculate their IC 50 inhibition, the experimental results shown in Table.
- the example compounds of the present invention have an inhibitory effect on the activity of SHP2, and preferably IC 50 is less than 50 nM.
- the luminescent cell viability test was used to evaluate the effects of the compounds of the present invention on the proliferation of NCI-H358 human non-small cell lung cancer cells.
- the compound was dissolved and diluted to 5mM in DMSO (Sigma, catalog number D5879), and then a 4-fold serial dilution was performed with DMSO to the lowest concentration of 0.31 ⁇ M, and RPMI 1640 medium (Thermo Fisher Scientific, catalog number) was used for each concentration point. 11995073) diluted 50 times. If the compound IC 50 value is low, the initial concentration of the compound can be reduced.
- NCI-H358 ATCC, catalog number CRL-5807 cells are cultured in RPMI 1640 complete medium [RPMI 1640 medium contains 10% FBS (GBICO, catalog number 10099-141) and 100 units/mL penicillin streptomycin mixture (Thermo Fisher Scientific, catalog number 15140122)].
- the compounds of the examples of the present invention have an inhibitory effect on cell proliferation, and preferably IC 50 is less than 1000 nM.
- the effect of the compounds of the present invention on possible arrhythmias was evaluated by measuring the blocking effect on the hERG potassium ion channel.
- Compound solution Dissolve the test compound in DMSO and make a 10 mM stock solution, then dilute it to 3 mM with DMSO, and then dilute it to a 3 ⁇ M solution with extracellular fluid for subsequent use.
- HEK293 cell line (Creacell, product number A-0320) stably overexpressing hERG potassium channels contains 10% fetal bovine serum (Gibco, product number 1428478) and 0.8 mg/mL G418 (Amresco, product number E859-5G).
- DMEM medium Gibco, catalog number 1009-141
- PBS Gibco, catalog number 1009-141
- TrypLE TM Express solution (Gibco, catalog number 12604021), and incubate at 37°C for 30 seconds.
- Whole-cell patch clamp voltage stimulation scheme for recording the whole-cell hERG potassium current when the whole-cell seal is formed, the cell membrane voltage is clamped to -80mV.
- the clamping voltage is depolarized from -80mV to -50mV and maintained for 0.5 seconds (as a leakage current detection), then stepped to 30mV and maintained for 2.5 seconds, and then quickly restored to -50mV and maintained for 4 seconds to excite the tail current of the hERG channel ( Peak tail current), the hERG potassium current is recorded every 10 seconds.
- the experimental data is collected by EPC-10 amplifier (HEKA) and stored in PatchMaster (HEKA v2x73) software.
- Sutter Instruments is used to draw a capillary glass tube (Sutter Instruments) into a recording electrode.
- the coverslip with the cells is removed from the 24-well plate placed in the incubator, and then placed under an inverted microscope.
- the whole-cell recording mode perform slow capacitance compensation and record the membrane capacitance and series resistance, during which no leakage compensation is given.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Description
化合物编号 | IC 50(nM) |
1. | 23 |
2. | 20 |
3. | 20 |
4. | 126 |
5. | 801 |
6. | 877 |
7. | 12 |
8. | 8.6 |
9. | 8.8 |
10. | 36 |
11. | 4.0 |
12. | 3.1 |
13. | 8.7 |
14. | 2.5 |
15. | 2.7 |
16. | 56 |
17. | 14 |
18. | 5.5 |
19. | 11 |
化合物编号 | IC 50(nM) |
1 | 310 |
2 | 383 |
3 | 434 |
4 | 2359 |
7 | 575 |
8 | 309 |
9 | 1345 |
10 | 1763 |
11 | 165 |
12 | 264 |
14 | 108 |
15 | 342 |
17 | 540 |
18 | 335 |
19 | 222 |
Claims (9)
- 一种通式(I)所示的化合物:或其可药用的盐、前药、稳定同位素衍生物、异构体及其混合物形式,其中:环A为苯环或6元杂芳环,环B为与环A稠合的5元杂芳环,所述苯环和杂芳环任选被一个或多个选自D、卤素、氰基、氧代、C 1-6烷基、C 3-6环烷基、4-7元杂环基、5-6元杂芳基、-OR a、-NR aR b、-C(O)R a、-C(O)NR aR b、-S(O) 2R a、-S(O) 2NR aR b、-NR aS(O) 2R b或-P(O)(CH 3) 2的取代基所取代,其中所述烷基、环烷基、杂环基和杂芳基任选被一个或多个选自D、卤素、氰基、氧代、C 1-6烷基、C 3-6环烷基、4-7元杂环基、-OR a、-NR aR b、-C(O)R a或-C(O)NR aR b的取代基所取代;R 1为H、D、氰基、C 1-2烷基、环丙基、-OR a、-NR aR b或-C(O)NR aR b,所述烷基和环丙基的一个或多个氢任选被一个或多个D或氟所取代;R 2为H、C 1-2烷基或环丙基,所述烷基和环丙基的一个或多个氢任选被一个或多个选自D、氟或羟基所取代;R 4a和R 4b各自独立地选自H、D、卤素、氰基、-OR a、-NR aR b、-C(O)R a、-C(O)NR aR b、C 1-6烷基、C 3-6环烷基、4-7元杂环基或5-6元杂芳基,但R 4a和R 4b不能同时为氰基、-OR a或-NR aR b,所述烷基、环烷基、杂环基和杂芳基任选被一个或多个选自D、卤素、氰基、氧代、C 1-6烷基、C 3-6环烷基、4-7元杂环基、5-6元杂芳基、-OR a、-NR aR b、-C(O)R a或-C(O)NR aR b的取代基所取代;R 4a和R 4b任选与其所联接的碳原子共同组成一个C 3-7碳环或4-8元杂环;R 5a、R 5b、R 6a和R 6b各自独立地选自H、D、氟或甲基;R a和R b各自独立地选自H、C 1-6烷基、C 3-6环烷基或4-7元杂环基,所述烷基、环烷基和杂环基任选被一个或多个选自D、氟、氰基、氧代、羟基、-OCH 3或-NH 2的取代基所取代。
- 根据权利要求1所述的化合物或其可药用的盐、前药、稳定同位素衍生物、异构体及其混合物形式,其为以下通式(II)的化合物:其中:环A为苯环或6元杂芳环,环B为与环A稠合的5元杂芳环,所述苯环和杂芳环任选被一个或多个选自D、卤素、氰基、氧代、C 1-6烷基、C 3-6环烷基、4-7元杂环基、5-6元杂芳基、-OR a、-NR aR b、-C(O)R a、-C(O)NR aR b、-S(O) 2R a、-S(O) 2NR aR b或-NR aS(O) 2R b的取代基所取代,其中所述烷基、环烷基、杂环基和杂芳基任选被一个或多个选自D、卤素、氰基、氧代、C 1-6烷基、C 3-6环烷基、4-7元杂环基、-OR a、-NR aR b、-C(O)R a或-C(O)NR aR b的取代基所取代;R 1为H、D、氰基、C 1-2烷基、-OR a或-NR aR b,所述烷基的一个或多个氢任选被一个或多个D或氟所取代;R 2为H或C 1-2烷基,所述烷基的一个或多个氢任选被一个或多个D或氟所取代;R 4a和R 4b各自独立地选自H、D、卤素、氰基、-OR a、-NR aR b、-C(O)NR aR b、C 1-6烷基、C 3-6环烷基、4-7元杂环基或5-6元杂芳基,但R 4a和R 4b不能同时为氰基、-OR a或-NR aR b,所述烷基、环烷基、杂环基和杂芳基任选被一个或多个选自D、卤素、氰基、氧代、C 1-6烷基、C 3-6环烷基、4-7元杂环基、5-6元杂芳基、-OR a、-NR aR b、-C(O)R a或-C(O)NR aR b的取代基所取代;R 4a和R 4b任选与其所联接的碳原子共同组成一个C 3-7碳环或4-7元杂环;R a和R b各自独立地选自H、C 1-6烷基、C 3-6环烷基或4-7元杂环基,所述烷基、环烷基和杂环基任选被一个或多个选自D、氟、氰基、氧代、羟基、-OCH 3或-NH 2的取代基所取代。
- 根据权利要求1或2所述的化合物或其可药用的盐、前药、稳定同位素衍生物、异构体及其混合物形式,其为以下通式(III)的化合物:其中:环A为苯环或6元杂芳环,环B为与环A稠合的5元杂芳环,所 述苯环和杂芳环任选被一个或多个选自D、卤素、氰基、氧代、C 1-6烷基、C 3-6环烷基、4-7元杂环基、5-6元杂芳基、-OR a、-NR aR b、-C(O)R a或-C(O)NR aR b的取代基所取代,其中所述烷基、环烷基、杂环基和杂芳基任选被一个或多个选自D、卤素、氰基、氧代、C 1-2烷基、-OR a或-NR aR b的取代基所取代;X为-O-或-CR 8aR 8b-;R 1为H、D、氰基、C 1-2烷基或-NR aR b,所述烷基的一个或多个氢任选被一个或多个D或氟所取代;R 2为H或C 1-2烷基,所述烷基的一个或多个氢任选被一个或多个D或氟所取代;R 7a、R 7b、R 8a、R 8b、R 9a和R 9b各自独立地选自H、D、卤素、氰基、C 1-2烷基或-OR c,所述烷基的一个或多个氢任选被一个或多个选自D、氟或羟基所取代,但R 7a和R 7a、R 8a和R 8b、R 9a和R 9b任选不能同时为-OR c;R a和R b各自独立地选自H、C 1-6烷基、C 3-6环烷基或4-7元杂环基,所述烷基、环烷基和杂环基任选被一个或多个选自D、氟、氰基、氧代、羟基、-OCH 3或-NH 2的取代基所取代;R c为H或C 1-2烷基,所述烷基的一个或多个氢任选被一个或多个D或氟所取代。
- 根据前述权利要求任一项所述的化合物或其可药用的盐、前药、稳定同位素衍生物、异构体及其混合物形式,其为以下通式(IV)的化合物:其中:环A为苯环或6元杂芳环,环B为与环A稠合的5元杂芳环,所述苯环和杂芳环任选被一个或多个选自D、卤素、氰基、氧代、C 1-2烷基、-OR a或-NR aR b的取代基所取代,其中所述烷基的一个或多个氢任选被一个或多个D或氟所取代;X为-O-或-CH 2-;R 1为H、D、C 1-2烷基或-NR aR b,所述烷基的一个或多个氢任选被一个或多个D或氟所取代;R 2为H或C 1-2烷基,所述烷基的一个或多个氢任选被一个或多个D或氟所取代;R 7为H、D或C 1-2烷基,所述烷基的一个或多个氢任选被一个或多个D或氟所取代;R a和R b各自独立地为H或C 1-2烷基,所述烷基的一个或多个氢任选被一个或多个D或氟所取代。
- 一种药物组合物,其包含权利要求1-5任一项所述的化合物或其可药用的盐、前药、稳定同位素衍生物、异构体及其混合物形式和一种或多种药学上可接受的载体和赋形剂。
- 一种药物组合物,所述药物组合物包含根据权利要求1-5任一项所述的化合物或其可药用的盐、前药、稳定同位素衍生物、异构体及其混合物形式和至少一种额外的药物,其中所述至少一种额外的药物包括但不限于化疗药物、靶向药物、DNA合成抑制剂、抗体药物、抗体药物偶联物、抗肿瘤药物、免疫抑制剂等。
- 根据权利要求1-5任一项所述的化合物或其可药用的盐、前药、稳定同位素衍生物、异构体及其混合物形式或根据权利要求6-7所述的药物组合物在制备用于治疗和/或预防与SHP2活性异常相关疾病的药物中的用途,所述疾病包括但不限于癌症,比如白血病、努南综合症、豹斑综合征、神经母细胞瘤、黑色素瘤、肺癌、乳腺癌、食道癌、结肠癌、头颈癌、胃癌等。
- 一种治疗和/或预防SHP2相关性疾病的方法,其包含治疗有效量的根据权利要求1-7任一项所述的化合物或其前药、稳定同位素衍生物、可药用的盐、异构体及其混合物形式,或包含所述化合物的药物组合物。
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP21741216.2A EP4092024A4 (en) | 2020-01-19 | 2021-01-13 | HETEROCYCLIC COMPOUND OF PYRIMIDINE-4(3H)-KETONE, METHOD FOR PREPARING IT AND ITS USE IN MEDICINE AND PHARMACOLOGY |
CN202180009655.3A CN114981268A (zh) | 2020-01-19 | 2021-01-13 | 嘧啶-4(3h)-酮类杂环化合物、其制备方法及其在医药学上的应用 |
AU2021208025A AU2021208025A1 (en) | 2020-01-19 | 2021-01-13 | Pyrimidine-4(3H)-ketone heterocyclic compound, preparation method therefor and use thereof in medicine and pharmacology |
MX2022008881A MX2022008881A (es) | 2020-01-19 | 2021-01-13 | Compuesto heterociclico de pirimidin-4(3h)-ona, metodo de preparacion del mismo y su uso farmaceutico. |
US17/793,571 US20230219946A1 (en) | 2020-01-19 | 2021-01-13 | Pyrimidin-4(3h)-one heterocyclic compound, preparation method thereof, and pharmaceutical use thereof |
KR1020227028172A KR20220130168A (ko) | 2020-01-19 | 2021-01-13 | 피리미딘-4(3h)-케톤 헤테로시클릭 화합물, 그의 제조 방법, 및 의약 및 약리학에서의 그의 용도 |
JP2022543700A JP2023511337A (ja) | 2020-01-19 | 2021-01-13 | ピリミジン-4(3h)-オンヘテロ環式化合物、その調製方法、およびその医薬的使用 |
CA3168452A CA3168452A1 (en) | 2020-01-19 | 2021-01-13 | Pyrimidin-4(3tf)-one heterocyclic compound, preparation method thereof, and pharmaceutical use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010056202.3 | 2020-01-19 | ||
CN202010056202.3A CN113135910A (zh) | 2020-01-19 | 2020-01-19 | 嘧啶-4(3h)-酮类杂环化合物、其制备方法及其在医药学上的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021143701A1 true WO2021143701A1 (zh) | 2021-07-22 |
Family
ID=76808550
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2021/071375 WO2021143701A1 (zh) | 2020-01-19 | 2021-01-13 | 嘧啶-4(3h)-酮类杂环化合物、其制备方法及其在医药学上的应用 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20230219946A1 (zh) |
EP (1) | EP4092024A4 (zh) |
JP (1) | JP2023511337A (zh) |
KR (1) | KR20220130168A (zh) |
CN (2) | CN113135910A (zh) |
AU (1) | AU2021208025A1 (zh) |
CA (1) | CA3168452A1 (zh) |
MX (1) | MX2022008881A (zh) |
WO (1) | WO2021143701A1 (zh) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022060836A1 (en) | 2020-09-15 | 2022-03-24 | Revolution Medicines, Inc. | Indole derivatives as ras inhibitors in the treatment of cancer |
WO2022060583A1 (en) | 2020-09-03 | 2022-03-24 | Revolution Medicines, Inc. | Use of sos1 inhibitors to treat malignancies with shp2 mutations |
WO2022133217A1 (en) * | 2020-12-18 | 2022-06-23 | Genzyme Corporation | Process for preparing shp2 inhibitors |
WO2022235864A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Ras inhibitors |
WO2022235870A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Ras inhibitors for the treatment of cancer |
WO2022235866A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
WO2023060253A1 (en) | 2021-10-08 | 2023-04-13 | Revolution Medicines, Inc. | Ras inhibitors |
WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
WO2023192112A1 (en) * | 2022-03-28 | 2023-10-05 | Genzyme Corporation | Process for preparing shp2 inhibitors |
WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015107495A1 (en) | 2014-01-17 | 2015-07-23 | Novartis Ag | N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2 |
WO2016203405A1 (en) | 2015-06-19 | 2016-12-22 | Novartis Ag | Compounds and compositions for inhibiting the activity of shp2 |
WO2017211303A1 (en) | 2016-06-07 | 2017-12-14 | Jacobio Pharmaceuticals Co., Ltd. | Novel heterocyclic derivatives useful as shp2 inhibitors |
WO2018013597A1 (en) | 2016-07-12 | 2018-01-18 | Revolution Medicines, Inc. | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors |
WO2018057884A1 (en) | 2016-09-22 | 2018-03-29 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of use thereof |
WO2018130928A1 (en) * | 2017-01-10 | 2018-07-19 | Novartis Ag | Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor |
-
2020
- 2020-01-19 CN CN202010056202.3A patent/CN113135910A/zh active Pending
-
2021
- 2021-01-13 AU AU2021208025A patent/AU2021208025A1/en active Pending
- 2021-01-13 CA CA3168452A patent/CA3168452A1/en active Pending
- 2021-01-13 MX MX2022008881A patent/MX2022008881A/es unknown
- 2021-01-13 US US17/793,571 patent/US20230219946A1/en active Pending
- 2021-01-13 WO PCT/CN2021/071375 patent/WO2021143701A1/zh unknown
- 2021-01-13 CN CN202180009655.3A patent/CN114981268A/zh active Pending
- 2021-01-13 JP JP2022543700A patent/JP2023511337A/ja active Pending
- 2021-01-13 EP EP21741216.2A patent/EP4092024A4/en active Pending
- 2021-01-13 KR KR1020227028172A patent/KR20220130168A/ko active Search and Examination
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015107495A1 (en) | 2014-01-17 | 2015-07-23 | Novartis Ag | N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2 |
WO2016203405A1 (en) | 2015-06-19 | 2016-12-22 | Novartis Ag | Compounds and compositions for inhibiting the activity of shp2 |
CN107787323A (zh) * | 2015-06-19 | 2018-03-09 | 诺华股份有限公司 | 用于抑制shp2活性的化合物和组合物 |
WO2017211303A1 (en) | 2016-06-07 | 2017-12-14 | Jacobio Pharmaceuticals Co., Ltd. | Novel heterocyclic derivatives useful as shp2 inhibitors |
CN109311848A (zh) * | 2016-06-07 | 2019-02-05 | 北京加科思新药研发有限公司 | 可用作shp2抑制剂的新型杂环衍生物 |
WO2018013597A1 (en) | 2016-07-12 | 2018-01-18 | Revolution Medicines, Inc. | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors |
WO2018057884A1 (en) | 2016-09-22 | 2018-03-29 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of use thereof |
WO2018130928A1 (en) * | 2017-01-10 | 2018-07-19 | Novartis Ag | Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor |
Non-Patent Citations (4)
Title |
---|
CHEN Y ET AL., NATURE, vol. 535, 2016, pages 148 - 52 |
LI J ET AL., CANCER RES, vol. 75, 2015, pages 508 - 518 |
RUESS DA ET AL., NAT. MED., vol. 24, 2018, pages 954 - 960 |
See also references of EP4092024A4 |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022060583A1 (en) | 2020-09-03 | 2022-03-24 | Revolution Medicines, Inc. | Use of sos1 inhibitors to treat malignancies with shp2 mutations |
WO2022060836A1 (en) | 2020-09-15 | 2022-03-24 | Revolution Medicines, Inc. | Indole derivatives as ras inhibitors in the treatment of cancer |
WO2022133217A1 (en) * | 2020-12-18 | 2022-06-23 | Genzyme Corporation | Process for preparing shp2 inhibitors |
WO2022235864A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Ras inhibitors |
WO2022235870A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Ras inhibitors for the treatment of cancer |
WO2022235866A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
WO2023060253A1 (en) | 2021-10-08 | 2023-04-13 | Revolution Medicines, Inc. | Ras inhibitors |
WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
WO2023192112A1 (en) * | 2022-03-28 | 2023-10-05 | Genzyme Corporation | Process for preparing shp2 inhibitors |
WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
Also Published As
Publication number | Publication date |
---|---|
CA3168452A1 (en) | 2021-07-22 |
MX2022008881A (es) | 2022-08-11 |
AU2021208025A1 (en) | 2022-09-01 |
CN114981268A (zh) | 2022-08-30 |
KR20220130168A (ko) | 2022-09-26 |
JP2023511337A (ja) | 2023-03-17 |
CN113135910A (zh) | 2021-07-20 |
EP4092024A1 (en) | 2022-11-23 |
US20230219946A1 (en) | 2023-07-13 |
EP4092024A4 (en) | 2024-03-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2021143701A1 (zh) | 嘧啶-4(3h)-酮类杂环化合物、其制备方法及其在医药学上的应用 | |
CA3054455C (en) | Fgfr inhibitor and application thereof | |
WO2021218110A1 (zh) | 一类苯并噻唑基联芳基类化合物、制备方法和用途 | |
RU2622104C2 (ru) | Макроциклические ингибиторы киназы lrrk2 | |
WO2021088945A1 (zh) | 作为shp2抑制剂的化合物及其应用 | |
RU2742485C2 (ru) | Гетероциклическое соединение, используемое как ингибитор fgfr | |
WO2021190417A1 (zh) | 新型氨基嘧啶类egfr抑制剂 | |
TWI828712B (zh) | 作為trk抑制劑的雜環化合物 | |
TW201443023A (zh) | 作爲rock抑制劑之酞□酮及異喹啉酮 | |
WO2016011979A1 (zh) | 2,4-二取代7H-吡咯并[2,3-d]嘧啶衍生物、其制法与医药上的用途 | |
WO2020207260A1 (zh) | 一种cdk激酶抑制剂及其应用 | |
JP2022523477A (ja) | ピロロピリミジン誘導体及びこれを有効成分として含有するタンパク質キナーゼ関連疾患の予防又は治療用薬学的組成物 | |
WO2022063212A1 (zh) | 嘧啶基衍生物、其制备方法及其用途 | |
WO2019080723A1 (zh) | 多取代吡啶酮类衍生物、其制备方法及其医药用途 | |
WO2022272106A1 (en) | Cdk2 inhibitors and methods of using the same | |
WO2021032004A9 (zh) | 氮杂芳基化合物及其应用 | |
WO2020238776A1 (zh) | 取代的稠合双环类衍生物、其制备方法及其在医药上的应用 | |
WO2019223777A1 (zh) | 一种含有芳胺基取代的吡咯并嘧啶类化合物、制备方法及其应用 | |
TW201835079A (zh) | 6-吡唑-[1,2,4]三唑並[4,3-α]吡啶-3-醯胺類衍生物、其製備方法及其在醫藥上的應用 | |
WO2023036252A1 (zh) | 吡咯并嘧啶类或吡咯并吡啶类衍生物及其医药用途 | |
CN116600808A (zh) | 一类作为kras突变体g12c抑制剂的四氢萘啶类衍生物、其制备方法及其应用 | |
WO2022007659A1 (zh) | 杂环类免疫调节剂 | |
WO2022063050A1 (zh) | 吡唑类化合物及其制备方法和用途 | |
CN114380818A (zh) | 吡唑并吡啶类化合物,及其药物组合物、制备方法和用途 | |
CN112694477B (zh) | 吡唑并环类化合物,包含其的药物组合物,其制备方法及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21741216 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3168452 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2022543700 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20227028172 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021208025 Country of ref document: AU Date of ref document: 20210113 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2021741216 Country of ref document: EP Effective date: 20220819 |